Monte Rosa Therapeutics (NASDAQ: GLUE) COO exercises options and sells 2,175 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an option exercise and related share sale in Common Stock. She exercised stock options for 2,175 shares at $3.98 per share and sold 2,175 shares in an open-market transaction at $20.00 per share.

After these transactions, she directly holds 62,371 shares of Common Stock and 35,649 stock options. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating a scheduled liquidity event rather than a discretionary trade.

Insider Trade Summary 10b5-1

Net Seller: 2,175 shares ($43,500)

Net Sell 3 txns

Insider Champoux Jennifer

Role Chief Operating Officer

Sold 2,175 shs ($44K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,175	$0.00	--
Exercise	Common Stock	2,175	$3.98	$9K
Sale	Common Stock	2,175	$20.00	$44K

Holdings After Transaction: Stock Option (Right to Buy) — 35,649 shares (Direct, null); Common Stock — 64,546 shares (Direct, null)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 2,175 shares Sale price: $20.00/share Shares acquired via option: 2,175 shares +4 more

7 metrics

Shares sold 2,175 shares Common Stock open-market sale on May 27, 2026

Sale price $20.00/share Price for 2,175 Common Stock shares sold

Shares acquired via option 2,175 shares Common Stock acquired through option exercise

Option exercise price $3.98/share Strike price for exercised stock option

Shares held after transactions 62,371 shares Direct Common Stock ownership following trades

Options remaining 35,649 options Stock options outstanding after reported exercise

Option expiration June 3, 2034 Expiration date of the option grant exercised

Key Terms

Rule 10b5-1 trading plan, open-market sale, Stock Option (Right to Buy), derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) with underlying security title Common Stock"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

non-derivative financial

"transaction_type: non-derivative for Common Stock entries"

Form 4 Insider Transactions: What Each Field Means →

05/28/2026 - 07:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Champoux Jennifer

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/27/2026		M⁽¹⁾		2,175	A	$3.98	64,546	D
Common Stock	05/27/2026		S⁽¹⁾		2,175	D	$20	62,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$3.98	05/27/2026		M⁽¹⁾			2,175	⁽²⁾	06/03/2034	Common Stock	2,175	$0	35,649	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

2. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Phil Nickson, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Monte Rosa Therapeutics (GLUE) report for COO Jennifer Champoux?

Monte Rosa Therapeutics reported that COO Jennifer Champoux exercised options for 2,175 shares and sold 2,175 shares of Common Stock. These transactions occurred on May 27, 2026 and were executed under a pre-arranged Rule 10b5-1 trading plan.

How many Monte Rosa Therapeutics (GLUE) shares did the COO sell and at what price?

COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics Common Stock at $20.00 per share. The sale was reported as an open-market transaction and formed part of a broader exercise-and-sell sequence under a Rule 10b5-1 trading plan.

What stock options did the Monte Rosa Therapeutics (GLUE) COO exercise in this Form 4?

Jennifer Champoux exercised stock options covering 2,175 shares of Monte Rosa Therapeutics Common Stock at an exercise price of $3.98 per share. These options are part of a grant that began vesting in May 2025 and expire on June 3, 2034.

How many Monte Rosa Therapeutics (GLUE) shares does the COO hold after the reported transactions?

Following the reported transactions, COO Jennifer Champoux directly holds 62,371 shares of Monte Rosa Therapeutics Common Stock. She also continues to hold 35,649 stock options, providing additional potential future equity exposure if those options are later exercised.

Were the Monte Rosa Therapeutics (GLUE) insider transactions made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnotes state that the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Jennifer Champoux on February 19, 2026. Such plans pre-schedule trades, reducing the significance of short-term market timing.

When do the Monte Rosa Therapeutics (GLUE) COO’s exercised options expire?

The stock options involved in the reported exercise expire on June 3, 2034. According to the footnotes, 25% vested on May 28, 2025 and the remainder vests in 36 substantially equal monthly installments, subject to continued service.